register

News & Trends - Pharmaceuticals

GPs left in the dark about major changes to opioid prescribing

Health Industry Hub | June 15, 2020 |

Pharma News: The Royal Australian College of General Practitioners (RACGP) is calling for improved communication to GPs after they were not adequately informed about major changes to prescription opioid prescribing.

It comes after the RACGP welcomed the changes to the Pharmaceutical Benefits Scheme (PBS) reducing opioid pack sizes, which came into effect on Monday 1st June. The changes were made in response to concerns about the high number of deaths and hospitalisations due to prescription opioids.

Although the changes came into effect on Monday 1st June, crucial information on what medications were affected was not adequately communicated to GPs ahead of time. Some GPs were unable to prescribe the new smaller pack sizes through their usual clinical software until an update was rolled out days after the regulations came into effect.

Register & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

A detailed listing of the changes to opioid medications only became available on the PBS website on Tuesday 2nd June. The Therapeutic Good Administration (TGA) issued a press release to publicise the changes the same day.

Chair of the RACGP’s Expert Committee on Quality Care Professor Mark Morgan said the poor communication had caused unnecessary grief for GPs and their patients.

“Many GPs were caught unaware of the changes until half way through the process of prescribing. GPs and clinic staff had to call the PBS Authority Prescription phone line for information. Some GPs had to hand-write authority prescriptions while waiting for clinic software updates.

“Vulnerable and stigmatised patients who were using opioids for non-cancer pain and happened to be trying to get medication were caught up in the middle and faced unnecessary upset.

“Changes to the PBS to change prescribing need to go hand in hand with a comprehensive communication strategy. These changes should have been rolled out with supporting education and publicity for GPs and pharmacists well ahead of the day they were due to come into effect, and ensuring clinical software vendors’ updates were ready to go.

“The communication needs to be nuanced, rather than demonising opioids. Over the last decade there has been a seismic shift in our understanding of the pros and cons of using opioids for non-cancer pain. We are now much more aware that for most, but not all patients, taking opioids long term makes precious little difference to their pain and wellbeing.”

Under the changes, opioid medications are now only available in smaller packs with no repeats for the treatment of non-chronic pain. Patients with long-term chronic pain can still access larger pack sizes and repeats when certain requirements are met.* It comes after increasing recognition that opioids are a poor choice for most types of pain.

Chair of the RACGP Addiction Medicine network Dr Hester Wilson welcomed the changes but says more must be done to combat harm from opioids.

“Limiting a patient’s access to opioids is a step towards combatting the associated harms but it’s not a silver bullet.

“Unfortunately, we know some people who have their prescriptions limited without a collaborative plan to manage this change, will struggle and may turn to black market alternatives. That’s why it’s essential that government ensures that education for GPs and adequate treatment services are available across Australia, because substance use affects all communities.

“We should also be more proactive in helping patients with alcohol and other drug problems. One way to make a big difference would be increasing access to naloxone for patients who need it, and to their loved ones – this drug can temporarily reverse an opioid overdose and saves lives but not enough people know about it. 

“Another important issue is improving access to Medication Assisted Treatment of Opioid Dependence; (methadone and buprenorphine).  This highly evidence based treatment improves health and wellbeing outcomes and is particularly effective for people who have developed an opioid use disorder through the use of prescription opioids for chronic pain.”

Dr Wilson said substance use needed to be treated seriously now more than ever, with reports that the COVID-19 pandemic has led to a noticeable increase in patients presenting with problematic use.

The College also recently launched an online education program for GPs to further enhance their skills in caring for patients with alcohol and other drug issues, including prescription opioid dependence or misuse.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.